Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02175121 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
A Phase 2 study of Diabetes Mellitus Type II, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 19
- Study locations
NCT02175121: Completed Phase 2 study of Diabetes Mellitus Type II, sponsored by Pfizer.
NCT02175121 is a Phase 2 study of Diabetes Mellitus Type II that has completed, run by Pfizer. The registered enrollment target is 172 participants, below the 216-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (20% lower). The trial reports 19 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02175121, a Phase 2 study of Diabetes Mellitus Type II, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.
Primary Outcome
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. An HAE was identified by characteristic symptoms or blood glucose levels. TEAEs are events between first d
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-06291874
Study Locations (19)
Florida
- Avail Clinical Research, LLC - DeLand
- SeaView Research, Inc. - Miami
- SeaView Research, Inc. - Miami
- Compass Research, LLC - Orlando
- Miami Research Associates, Inc. - South Miami
- MRA Clinical Research, LLC - South Miami
- MRA Clinical Research - South Miami
California
- Anaheim Clinical Trials, LLC - Anaheim
- Profil Institute for Clinical Research, Inc. - Chula Vista
- Diablo Clinical Research, Inc. - Walnut Creek
New Jersey
- Clinilabs, Inc. - Eatontown
- PRA International - Marlton
Kentucky
- Louisville Metabolic and Atherosclerosis Research Center - Louisville
Minnesota
- DaVita Clinical Research - Minneapolis
New York
- Buffalo Clinical Research Center, LLC - Buffalo
North Carolina
- High Point Clinical Trials Center, LLC - High Point
Ohio
- Community Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT02175121 record still lists
NCT02175121 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 216-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Diabetes Mellitus Type II appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02175121 lists 19 locations in 10 states (Florida, California, New Jersey).
Frequently Asked Questions
What is clinical trial NCT02175121 about?
NCT02175121 is a clinical study titled "Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus". This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.
What is the current status of trial NCT02175121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2014-08. Estimated completion is 2015-03.
What conditions does trial NCT02175121 study?
This clinical trial studies the following conditions: Diabetes Mellitus Type II.
What interventions are being tested in trial NCT02175121?
The interventions under investigation include: Placebo (DRUG), PF-06291874 (DRUG).
Who is sponsoring clinical trial NCT02175121?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02175121 being conducted?
This trial has 19 study locations across California, Florida, Kentucky, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus Type II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 2
-
Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery
RECRUITING · NA
-
Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana
ACTIVE NOT RECRUITING
-
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
-
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
COMPLETED · Phase 4
-
GOLO Open-Label Pilot 1
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia